[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.195.49. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 299
Citations 0
In This Issue of JAMA Ophthalmology
November 2017

Highlights

JAMA Ophthalmol. 2017;135(11):1135. doi:10.1001/jamaophthalmol.2016.3762

Koh and coauthors evaluate whether there are any differences in treatment outcomes between combination therapy of intravitreal ranibizumab plus verteporfin photodynamic therapy compared with ranibizumab monotherapy for polypoidal choroidal vasculopathy in a multicenter randomized clinical trial. Among 322 Asian participants, treatment of polypoidal choroidal vasculopathy with ranibizumab plus verteporfin photodynamic therapy resulted in greater visual acuity improvement with monotherapy and greater likelihood of resolution of polypoidal lesions on indocyanine green angiography using fewer ranibizumab injections. These data suggest ranibizumab plus verteporfin photodynamic therapy should be considered as a viable treatment strategy for eyes with polypoidal choroidal vasculopathy.

Invited Commentary

×